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Introduction
Muckle-Wells syndrome (MWS) is an inherited autoin-
flammatory disease (SAID) caused by NLRP3 gene muta-
tions, which results in excessive interleukin-1b (IL-1)
secretion. MWS is characterized by recurrent bouts of
systemic inflammation, resulting in fever, rash and joint
pain. Main complications include sensorineural deafness
and amyloidosis. Infertility was mentioned in the first
description of MWS but this complication has never
been thoroughly studied. Interleukin-1 targeting drugs
were shown to alleviate the clinical symptoms of MWS
patients and to improve their quality of life, but nothing
is known on its potential ability to reverse infertility.
Aims
To assess the fertility of male patients with MWS and to
analyse the effect of anti-IL1 on male MWS infertility
Methods
Medical records of male MWS patients followed in our
tertiary center for SAID were reviewed retrospectively
for data indicating fertility problems. When patients
agreed spermiograms were performed.
Results
Seven patients (17y, 21y, 31y, 43y, 45y, 46y, 47y) were
identified. All carried R260W NLRP3 mutations and pre-
sented typical clinical and biological signs of MWS. None
had amyloïdosis or risk factors for infertility. Four patients
having regular sexual activity were unable to have children
after 2 years; two used in vitro fertilisation with donor
sperms. Spermiograms (available in 5 patients) showed
azoospermia (3 patients) and oligospermia (2 patients). In
three patients spermiograms were available before and
after treatment with canakinumab. Two patient had been
treated with anakinra, an IL-1 receptor antagonist, during
2 years, prior to be switched to canakinumab. All three
patients received canakinumab during 2-4 years. Canaki-
numab induced clinical and biological remission but did
not change azoospermia or oligospermia.
Conclusions
Male MWS patients may be sterile. Better knowledge on
the natural history of azoospermia would help to discri-
minate the respective role of NLRP3 mutation, chronic
inflammation, and other factors. Late intervention by
IL-1 blockade treatment seems to be ineffective. Addi-
tional studies are required to better establish the fre-
quency of infertility and to investigate whether early
treatment with interleukin-1 targeting drugs before pub-
erty may prevent sterility.
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